sitagliptin-phosphate has been researched along with Vascular-Calcification* in 1 studies
1 other study(ies) available for sitagliptin-phosphate and Vascular-Calcification
| Article | Year |
|---|---|
Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice.
Diabetes is a complex disease characterized by hyperglycemia, dyslipidemia, and insulin resistance. Plasma advanced glycation end products (AGEs) activated the receptor for advanced glycation end products (RAGE) and the activation of RAGE is implicated to be the pathogenesis of type 2 diabetic mellitus (T2DM) patient vascular complications. Sitagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, is a new oral hypoglycemic agent for the treatment of T2DM. However, the beneficial effects on vascular calcification remain unclear. In this study, we used a high-fat diet (HFD)-fed low-density lipoprotein receptor deficiency (LDLR Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Glycation End Products, Advanced; Mice; Mice, Knockout; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, LDL; Sitagliptin Phosphate; Vascular Calcification | 2021 |